Radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8 90yttrium anti-CD20 monoclonal antibody.

被引：0
|
作者：
Wiseman, G
Witzig, T
White, CA
Solinger, A
Gordon, L
Raubitschek, A
Emmanouilides, C
Gutheil, J
Parker, E
Chinn, P
Grillo-Lopez, A
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Idec Pharmaceut Corp, San Diego, CA USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[5] Univ Calif Los Angeles, Los Angeles, CA USA
[6] Sidney Kimmel Canc Ctr, San Diego, CA USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 1998年 / 13卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [31] IDEC-C2B8 anti-CD20 immunotherapy in patients with non-Hodgkin's lymphoma (NHL): Hematological effects in the bone marrow and peripheral blood.
    Nguyen, D
    Amess, J
    Doughty, H
    Foran, J
    Lister, TA
    BLOOD, 1997, 90 (10) : 2276 - 2276
  • [32] Combination anti-CD20 immunotherapy and pretargeted anti-CD20 radioimmunotherapy (PT-RAIT) of non-Hodgkin lymphoma (NHL) shows improved efficacy
    Goldenberg, David M.
    Karacay, Habibe
    Chang, Chien-Hsing
    Rossi, Edmund A.
    McBride, William J.
    Sharkey, Robert M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [33] Localization of yttrium 90 ibritumomab tiuxetan (90Y IT) in patients with CD20+ non-Hodgkin's lymphoma (NHL).
    Jacobs, SA
    Swerdlow, SA
    Avril, N
    Vidnovic, N
    Foon, KA
    Harrison, AM
    McCarty, KS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 177S - 177S
  • [34] Y-90 Zevalin (anti-CD20) Radioimmunotherapy for adults with relapsed/refractory Hodgkin's disease
    Lastoria, S.
    Aloj, L.
    Caraco, C.
    Tommaselli, A.
    Frigeri, F.
    Pinto, A.
    De Martinis, F.
    Casale, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S240 - S240
  • [35] Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma
    White, CA
    Larocca, A
    Grillo-López, AJ
    PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (03): : 95 - 101
  • [36] Anti-CD20 monoclonal antibody (rituximab) associated to mine and autotransplantation in patients with relapsed or primary refractary follicular or transformed follicular non-Hodgkin lymphoma (NHL).
    Solano, C
    Gutiérrez, AM
    Benet, I
    Marugán, I
    Tormo, M
    Terol, MJ
    Prósper, F
    García-Conde, J
    BLOOD, 1999, 94 (10) : 406B - 406B
  • [37] Radioisotopic Localization of 90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma
    S. A. Jacobs
    A. M. Harrison
    S. H. Swerdlow
    K. A. Foon
    N. Avril
    N. Vidnovic
    J. Joyce
    N. DeMonaco
    K. S. McCarty
    Molecular Imaging and Biology, 2009, 11 : 39 - 45
  • [38] IDEC-C2B8 chimeric anti-CD20 antibody (MAB): Safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL)
    GrilloLopez, AJ
    Varns, C
    Waldichuk, C
    Dallaire, BK
    Rosenberg, J
    McClure, A
    Shen, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1072 - 1072
  • [39] Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
    Piro, LD
    White, CA
    Grillo-López, AJ
    Janakiraman, N
    Saven, A
    Beck, TM
    Varns, C
    Shuey, S
    Czuczman, M
    Lynch, JW
    Kolitz, JE
    Jain, V
    ANNALS OF ONCOLOGY, 1999, 10 (06) : 655 - 661
  • [40] Radioimmunotherapy with iodine-131 anti-CD20 chimeric monoclonal antibody (rituximab) for relapsed or refractory indolent non-Hodgkin's lymphoma: Results of an Australian phase II trial
    Leahy, MF
    Seymour, JF
    Hicks, RJ
    Turner, JH
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 156
12345